Interplay between cancer epithelial cells and the surrounding immune cells shape the tumor microenvironment to promote cancer progression. Tumor-associated macrophages are well recognized for their roles in cancer progression. Accumulating evidence also indicates implication of Rab small GTPase-mediated exocytosis in tumorigenesis. However, the mechanism for Rab-mediated exocytosis in regulation of macrophage polarization is not clear. We have previously identified Rab37 as a metastasis suppressor in lung cancer. In our study, we identified a novel Rab37 trafficking cargo soluble ST2 (sST2), which skewed macrophage polarization toward anti-tumoral M1-like phenotype in vitro. We further demonstrated that Rab37-mediated sST2 secretion significantly increased the ratio of M1 vs. M2 in xenografts and thus reduced tumor growth. Moreover, lung cancer patients with low Rab37, low sST2 and low ratio of M1 vs. M2 macrophages expression profile correlated with worse overall survival examined by Kaplan-Meier survival analysis. Multivariate Cox regression analysis showed that this Rab37-sST2-M1/M2 expression profile predicted poor prognosis. Our findings reveal a novel regulation of cancerous Rab37 in microenvironmental macrophages polarization, which preferentially shifts to anti-tumoral phenotype and thereby suppresses lung tumor growth.
Introduction
Tumor cells shape tumor microenvironment for promoting tumor development and metastasis by releasing soluble substances to modulate stromal cells activation, such as endothelial cells, pericytes, fibroblast and immune cells. 1 Among immune cells recruited to tumor region, macrophages are the most abundant cell type and play critical roles during tumor progression. 2 Tumor-associated macrophages (TAM) are divided into anti-tumoral M1 and pro-tumoral M2 subtypes. M1 macrophages exert tumoricidal activity by producing pro-inflammatory cytokines, reactive oxygen species, reactive nitrogen intermediates as well as efficient antigen presentation on major histocompatibility complex, resulting in cytotoxic T lymphocytes activation. 3 In contrast, alternatively activated M2 macrophages induced by interleukin 4 (IL-4), IL-13 and IL-33 possess the ability to support angiogenesis and to suppress immunostimulation in tumor microenvironment and thereby promote tumor progression. 4 IL-33 belongs to the IL-1 family of cytokines and associates with M2 macrophages polarization. 5, 6 Interleukin-1 receptor like 1 (IL1RL10), also named as ST2, is the natural receptor of IL-33. Three isoforms of ST2 have been identified, ST2L (transmembrane form), sST2 (soluble form) and ST2V (a variant ST2). 7 Soluble and membrane-bound isoforms of ST2 are generated by alternative splicing. Their distal promoter regulates ST2L expression, while the proximal promoter controls soluble ST2 induction. 8, 9 Soluble ST2 contains a unique C-terminal sequence contained within the structure of ST2L. 10 IL-33 binds to ST2L
that is generally located on the surface of macrophages to activate downstream signaling resulting in M2 polarization. However, sST2 derived from epithelial cells and fibroblasts acts as a decoy receptor by interrupting the IL-33/ST2L axis. 11 Nevertheless, few studies on the role of IL-33/ST2 in tumor progression have been conducted. Inhibition of primary tumor growth as well as low frequency of metastases are observed in ST2 knockout mice with breast cancer cells implantation. 12 In addition, breast cancer growth and metastases are promoted by IL-33/ST2 axis-mediated immunosuppressive effect in tumor microenvironment. 13 Furthermore, increased intratumoral IL-33 and ST2 expression correlates with higher densities of microvessels in colorectal cancers. 14 The secretion of IL-33 by pericytes through PDGF-BB-SOX7 signaling in tumor microenvironment has been reported to induce TAMs recruitment. 15 It has also been demonstrated that elevated level of sST2 in tumor region modulated tumor microenvironment by suppressing IL-33-induced M2 macrophages infiltration, and thereby inhibiting tumor progression. 11 Although the critical role of sST2 in the shift of tumor microenvironment to the anti-tumoral state has been shown, the mechanism responsible for sST2 secretion remains poorly defined. Rab small GTPases function as regulators of vesicles transport, proteins trafficking, membrane targeting and membrane fusion. [16] [17] [18] [19] Rab GTPases cycle between active GTP-bound state and inactive GDP-bound state. 20 Emerging evidence
show that dysregulated function of Rab GTPases is implicated in tumorigenesis. Indeed, several Rab proteins including Rab2A, Rab3D, Rab8, Rab11, Rab21, Rab23, Rab25, Rab27B and Rab35 promote tumor cell migration, invasion and metastasis by regulating intracellular signal transduction and vesicles trafficking. [21] [22] [23] [24] [25] [26] [27] [28] [29] By contrast, a minor fraction of Rab proteins is proposed to serve as tumor suppressors. For example, Rab25 suppresses angiogenesis and malignant tumor formation in esophageal squamous cell carcinoma and colorectal carcinoma, respectively.
30,31
We previously demonstrated that Rab37 was downregulated by promoter hypermethylation in non-small cell lung cancer patients. Low level of Rab37 mRNA expression was associated with tumor metastasis. 32 We also showed that the small GTPase Rab37 regulates exocytosis of tumor cells to suppress metastasis by inhibiting cell motility through tissue inhibitor of metalloproteinase 1 (TIMP1) secretion and blocking neovasculature by releasing thrombospondin-1 (TSP1). 33, 34 These results suggest that Rab37 mediates the cross-talk between cancer cells and their surrounding stroma via exocytosis of specific cargos. Since the interplay between cancer cells and macrophages is the major determinant in the shaping of tumor microenvironment, little is known about the regulation of macrophages polarization by cancer cell-triggered exocytosis. In this report, we show that Rab37 in cancer cells mediates exocytic transport of sST2 to skew macrophages polarization toward M1-like phenotype and thereby suppresses lung tumor malignancy.
Materials and Methods

Cell lines
Human lung cancer cell line PC-14 and H460 lung cancer cell line were purchased from American Type Culture Collection (Rockville, MD). PC-14 cell line was maintained in DMEM (Gibco, Waltham, MA) supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and 1% penicillin/streptomycin (Gibco). H460 and Human Monocytic U937 cell lines were maintained in RPMI (Gibco) with 10% FBS (Gibco), 1% penicillin/streptomycin (Gibco) and 1% sodium pyruvate (Gibco). For U937 differentiation, we treated U937 with 100 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, St. Louis, MO) for 48 hr.
Plasmids, RNAi and transfection
The stable empty vector (EV), Rab37-wild type (WT), GTPbound constitutive active (Q89L) or GDP-bound dominant negative (T43N) cells were generated as described previously. 33 The shRNA lentivirus for Rab knockdown, shRab#1, shRab#2 or sh-ST2 was obtained from the National RNAi core Facility (Institute of Molecular Biology, Academia Sinica, Taiwan). Plasmids pEF6-V5-His-sST2 (mouse and human) and pEF6-Flag-HissST2 (mouse) for generating sST2-expressing cells were obtained from Dr. Morisada Hayakawa and Dr. Shin-ichi Tominaga (Division of Medical Biochemistry, Jichi Medical University, Tochigi, Japan). 35, 36 Plasmid transfection was carried out with Turbofect (Thermo Fisher Scientific, Danvers, MA) according to the manufacturer's protocol.
Macrophage education
Macrophages (1 3 10 6 ) differentiated from U937 were grown in conditioned medium (CM) derived from Rab37-manipulated What's new? Cancer cells shape the tumor microenvironment to promote malignancy through secretion of soluble factors. However, little is known about the suppression of tumor progression via cancer-secreted factors. Here, the authors provide evidence from cellbased, animal, and clinical studies that a small GTPase Rab37 mediates the exocytosis of soluble ST2 from lung cancer cells to skew macrophages towards M1-like tumor-suppressive phenotype, thus reducing tumor growth. Low expression of Rab37 and ST2 together with low ratio of M1/M2 macrophages correlates with poor overall survival. The Rab37/sST2 axis provides a link for the crosstalk between cancer and immune cells in the tumor microenvironment.
cancer cells supplemented with 10% FBS (Gibco) for seven days. Macrophages that were educated by CM derived from EV or Rab37-WT PC-14 additionally received 40 ng/ml IL-4 (PeproTech, Rocky Hill, NJ) to activate M2 polarization.
Immunohistochemistry assay (IHC)
Tissue sections were dewaxed, rehydrated and antigen retrieved. After blocking, the slides were incubated with primary antibodies against Rab37, ST2 or macrophage markers overnight at 48C. The peroxidase activity was visualized using diaminobenzidine tetrahydroxychloride (DAB) solution. The sections were counter stained with hematoxylin. Images were obtained by TissueFax instrument and quantified by the HistoQuest software for IHC (TissueGnostics, Vienna, Austria). The mean intensity was calculated within the selected gates: 0.3 mm 3 0.3 mm for Rab37 and ST2; 0.4 mm 3 0.4 mm for CD86 and CD206. Six gates were selected from an individual tissue slide. The threshold of immunohistochemical signal to distinguish positive from negative staining was determined by calculating the mean intensities of nonreactive isotype control antibodies in a total of five tissue slides. In our study, the mean and standard deviation of control antibodies were 20 6 8. The positive staining of examined proteins was defined as more than two standard deviations above the mean level of control antibodies, i.e., 40. The number of positive staining for CD86 or CD206 was calculated within the selected gates, and the ratio of M1/M2 (CD86/CD206) above one was designated as (1) . High Rab37 or ST2 expression was defined as more than the value of 50 among those positive staining samples and was designated as (H) as opposed to low expression (L). The antibodies used and the experimental conditions are listed in Supporting Information Table S1 .
RNA extraction and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assay Total RNA was extracted using Trizol reagent (Invitrogen, Foster City, CA). qRT-PCR was performed to analyze the mRNA expression of M1-and M2-like macrophage-specific genes by using SYBR Green Master Mix (Invitrogen). Results were normalized to those of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primers used for qRT-PCR analysis are listed in Supporting information Table S2 .
Animal studies
All animal experiments were performed in compliance with the institutional guidelines. Three sets of in vivo experiments were conducted. The first group included EV, Rab37-WT PC-14 cells (1 3 )/2. The mice were sacrificed after 4-6 weeks and the primary tumor tissues were resected, fixed and embedded in paraffin for IHC staining or histological hematoxylin and eosin staining.
Clinical samples and statistical analysis
We recruited 122 lung cancer patients from National Cheng Kung University Hospital (NCKUH), Taiwan after obtaining appropriate institutional review and informed consent from patients. Our study was approved by the Institutional Review Board of NCKUH (B-ER-103-369). All clinical samples used were conducted in accordance with the guidelines of the Declaration of Helsinki. Pearson v 2 test was used to compare the correlation of Rab37, ST2 protein expression and macrophage populations in lung cancer patients. Overall and disease-free survival curves were calculated according to the Kaplan-Meier method, and comparison was performed using the log-rank test. Cox regression comparison was performed to analyze the relative risk for poor outcome in patients. Two-tailed Student's t-test was used in three-independent cell studies and each group animal studies unless indicated otherwise. Data represented mean and SD. The level of statistical significance was taken as p-values, *p < 0.05; **p < 0.01; ***p < 0.001.
Results
Rab37 promotes M1-like macrophage infiltration and suppresses tumor growth
To understand the influence of Rab37 in lung cancer cells on shaping tumor microenvironment during tumor progression, nude mice were injected subcutaneously with PC-14 cells stably expressing empty vector (EV) or wild-type Rab37 (Rab37). Cells with overexpression of Rab37 showed significant reduction in tumor growth in vivo compared to EV group (Fig. 1a) , although similar in vitro proliferation rate was observed in these cells (Supporting Information Fig. S1a ). Accordingly, H460 lung cancer cells stably expressing scramble target (shC) or shRNA targeting Rab37 (shRab37#1 or shRab37#2) did not show significant difference in proliferation in vitro (Supporting Information Fig. S1b ), but increased in vivo tumor growth of shRab37#1 cells compared to shC cells was observed (Fig. 1b) . These results suggested that Rab37 in lung cancer cells modulated a tumor-suppressing microenvironment in vivo.
Since tumor-associated macrophages (TAMs), including tumor-suppressing M1 and tumor-promoting M2 subtypes, shape tumor microenvironment to regulate tumor progression, 1 we therefore interrogated whether Rab37 in cancer cells orchestrated TAMs infiltration in tumor region. Indeed, immunohistochemistry (IHC) analysis showed that a reduction of F4/80 1 macrophages infiltration was observed in xenografts derived from PC-14 cells stably expressing Rab37 (Rab37) compared to those with EV control (Supporting
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Information Fig. S2a ), whereas xenografts derived from Rab37 knockdown cells (shRab37#1) exhibited an increase in F4/80 1 staining in the intratumor regions (Supporting Information Fig. S2a ), indicating that Rab37 in tumor cells suppressed TAMs infiltration. We further examined the M1 and M2 subtypes of TAMs in xenografts derived from Rab37 manipulated cells. A higher ratio of CD86 1 M1-like subtype to CD206
1 M2-like macrophages was observed in Rab37 expressing cells-derived xenografts compared to EV group (Fig. 1c) . In contrast, xenografts derived from shRab37#1 cells exhibited low M1/M2 ratio (Fig. 1d) . Taken together, these findings suggested that Rab37 in cancer cells suppressed tumor growth by modulating the ratio of M1/M2 macrophages in tumor microenvironment.
Rab37-mediated cargo secretion inhibits M2 macrophage polarization
Since Rab37 is a critical regulator of exocytic pathway, we hypothesized that Rab37-mediated exocytosis is involved in macrophages polarization toward M1-like phenotypes. To test this hypothesis, we cultured human monocyte-derived macrophages with conditioned medium (CM) from Rab37-expressing PC-14 lung cancer cell lines. Macrophages treated with CM from Rab37-expressing cells exhibited increased levels of M1 genes expression (IL-6, IL-12 and TNF-a) and suppressed a panel of M2 gene expression (Arg1, Fizz1 and IL-10) (Figs. 2a and 2b) . In contrast, CM derived from Rab37 knockdown H460 cancer cells (shRab37#1 and shRab37#2) preferentially skewed macrophages polarization toward M2-like phenotypes (Figs. 2c and 2d ). These results indicated that CM from Rab37-expressing lung cancer cells suppressed expression of M2 specific genes in macrophages.
M2 macrophage-derived secreted factor has been shown to promote tumor cell migration. 37 To determine whether the CM-treated macrophages possessed M2-like ability, viz., stimulation of cancer cell mobility, we performed transwell migration assay using H460 cancer cells and supernatant from macrophages treated with CM from cancer cells with overexpression of Rab37 or silenced. As shown in Figure 2 , supernatant of macrophages educated by CM from Rab37 overexpressing cancer cells (CM: Rab37-Mu) exhibited a significant suppression of cancer cell motility, whereas supernatant of macrophages treated with CM from Rab37-silenced cancer cells (CM: shRab37#1-Mu or CM: shRab37#2-Mu) attracted more cancer cells moving through insert by enhancing their motility (Figs. 2e and 2f) . These results revealed that Rab37-mediated cargo proteins secretion into CM to increase the population of M1-like macrophages thereby inhibiting the migration of co-cultured cancer cells.
Next, we tested whether macrophages educated by CM from Rab37 knockdown cancer cells possessed the potential to promote tumor growth and metastasis in vivo. To this end, nude mice were co-injected with cancer cells and educated macrophages (shRab37#1 CM-Mu or shRab37#2 CMMu) subcutaneously to investigate tumor growth in vivo. The results showed that cancer cells co-injected with shRab37 (#1 or #2) CM-educated macrophages displayed significantly increased tumor growth (Fig. 2g ) and tumor weight (Fig. 2h) , and showed more lung metastatic nodules than those with control group (shC CM-Mu) (Figs. 2i and 2j) . Thus, exposure to CM from Rab37-silenced cancer cells induced the functional activation of M2 macrophage and consequently promoted tumor growth ability and tumor metastatic potential. Cytokine/chemokine profiling and conditioned media immunoblotting validate Rab37-mediated exocytosis of sST2
To identify the factors secreted by Rab37-mediated trafficking that regulate macrophages polarization, the cytokine/chemokine profiles of CM derived from EV-and Rab37-expressing PC-14 cells and CM from shC and shRab37#1 H460 cells were analyzed by antibody array. The array data revealed that the level of sST2 increased in CM from Rab37-expressing cancer cells compared to that from EV control group, while sST2 expression decreased in CM from Rab37-silenced cancer cells. The positive correlation of sST2 in the CM with Rab37 expression from Rab37-manipulating cancer cells was validated by immunoblotting (Supporting Information Fig. S3a) .
To further examine the connection between secretion of sST2 and Rab37 small GTPase activity, we reconstituted the expression of Rab37-EV, -WT, GTP bound-constitutive active Q89L or GDP bound-dominant negative T43N in shRab37#1 H460 cells. Low amount of sST2 in CM was found after re-expression of Rab37-EV in the cells deficient in Rab37 (lanes 2 vs. 1), while the levels of sST2 in CM were rescued in cells with reconstitution of Rab37-WT and -Q89L (lanes 3 and 4), but not in Rab37-T43N cells (lane 5) (Supporting Information Fig. S3b) . Furthermore, images of immunofluorescence (IF) staining illustrated the colocalization of Rab37 and sST2 in Rab37-WT and -Q89L cells, while a few colocalization signals were observed in Rab37-T43N cells (Supporting Information Fig. S3c) . Together, these results suggested that Rab37 regulated sST2 secretion in a GTP nucleotide-dependent manner.
Rab37-mediated exocytosis of sST2 to inhibit M2 macrophage polarization and suppress tumor growth
To investigate whether Rab37-mediated exocytosis of sST2 inhibited M2-type macrophage polarization, the level of sST2 was reduced by shRNA-based knockdown in Rab37-expressing PC-14 cells (Rab37-shST2). CM from Rab37-shST2 cells was collected and used to educate macrophages. As expected, macrophages treated with CM from Rab37-expressing cancer cells displayed elevated M1-specific genes expression, such as IL-6, IL-12 and TNF-a. In contrast, M2-type markers of macrophages (Arg1, Fizz1 and IL-10) showed reduced expression under this condition. Interestingly, these gene expression patterns were rescued by treatment with CM derived from Rab37-shST2 cells (Figs. 3a and 3b) . In addition, the transwell migration ability of cancer cells was suppressed by supernatant of macrophages educated by CM from Rab37-WT cells (CM: Rab37-Mu). This suppression of cancer cells motility was abrogated by knocked down of sST2 (CM: Rab37-shST2-Mu) (Fig. 3c) .
Moreover, we utilized these cancer cells manipulated for Rab37 and sST2 expression in animal experiments to examine whether Rab37-mediated suppression of tumor growth was through sST2. EV-, Rab37-expressing or Rab37-shST2 PC-14 cells were injected subcutaneously into both flanks of nude mice. The tumor growth curves of respective group showed that Rab37-expressing cells delayed tumor growth compared to EV group, whereas silencing of ST2 abolished the tumor suppressing ability of Rab37-expressing PC-14 cells (Figs. 3d and 3e) . A high ratio of M1/M2 macrophages was observed in Rab37-expressing-derived xenografts compared to EV or Rab37-shST2 group (Fig. 3f) .
We also collected CM from shC or shRab37 H460 cells with overexpression of sST2 (shRab37#1-sST2) to treat macrophages. Gene expression of M1-type macrophages was increased in sST2-expressing shC group (shC-sST2), while the expression of M2-specific markers was inhibited (Figs. 4a  and 4b ). However, CM from shRab37#1-sST2 group did not induce either M1-or M2-type changes in gene expression profiling when compared to Rab37 knockdown alone group (shRab37#1) (Figs. 4a and 4b) . These results suggested that Rab37-mediated sST2 secretion skewed macrophages toward M1-like phenotype and the ability of sST2 to influence macrophage polarization is Rab37-dependent. Transwell migration data showed that CM from reconstituted sST2 expression in shC (CM: shC-sST2-Mu) but not shRab37 groups (CM:shRab37#1-Mu and CM:shRab37#1-sST2-Mu) inhibited the motility of H460 cells (Fig. 4c) . In contrast, overexpression of sST2 in Rab37-silencing H460 cells (shRab37#1-sST2) failed to suppress tumor growth in xenografts compared to control group with overexpression of sST2 (shC-sST2) (Figs. 4d and 4e) . Taken together, these data indicated that M2 macrophage polarization, cancer cells migration and primary tumor growth were suppressed by Rab37 through mediating the exocytosis of sST2 and such effects of sST2 is Rab37-dependent.
Concordant expression of Rab37 and ST2 together with high ratio of M1/M2 macrophage correlates with better prognosis
We further performed IHC analysis on samples from 122 lung cancer patients to determine the correlation between Rab37 and sST2 by assigning protein expression levels into preserved and low expression (Fig. 5a) . The results showed that low Rab37 protein expression was detected in 48 patient specimens (39.3%), while low sST2 secretion was observed in 49 of them (40.2%) (Supporting Information Table S3 ). Strikingly, a strong positive correlation between Rab37 and sST2 expression was observed (74.6%, p < 0.001; Fig. 5b ). Of note, patients with low Rab37 expression or low sST2 level were associated with advanced tumor stage (stages III and IV; Information Table S3 ; Fig. 5c ). Importantly, patients with low expression of Rab37 or sST2 individually or together, showed significantly worse overall (n 5 122, p 5 0.005 for Rab37; p 5 0.044 for sST2; p 5 0.003 for both) and progression-free survival (n 5 116, p 5 0.043 for Rab37; p 5 0.016 for sST2; p 5 0.025 for both) than those with preserved expression of both proteins (Supporting information Fig. S4) .
Since Rab37-mediated sST2 secretion to inhibit M2 macrophage polarization and hence reduced malignant tumor growth, we further examined whether poor survival was observed in patients with low expression of both Rab37 and sST2 proteins together with low ratio of M1/M2 macrophages in tumor specimens. For this, we detected the expression of Rab37, sST2, CD86 (for M1-like macrophages) and CD206 (for M2-like macrophages) in lung tumor specimens by IHC analysis (Fig. 5d) . Strikingly, the result showed that patients with concordant low expression of both Rab37 and sST2 combined with low ratio of M1/M2 macrophages had worse overall survival (p 5 0.003) (Fig. 5e) .
To further investigate whether low expression of both Rab37 and sST2 together with low ratio of M1/M2 macrophages serves as an independent prognostic factor of lung cancer patients, univariate and multivariate Cox regression analysis were performed. Univariate Cox regression analysis showed that patients with low Rab37, sST2 expression and low M1/M2 ratio as well as other clinical characteristics including smoking habit, overall late stage, advanced TNM stages had higher risk of poor survival than those without these clinical parameters (Table 1) . Remarkably, multivariate Cox regression analysis by including all variables with a significant association in univariate analysis showed that patients with concordant low Rab37 and sST2 expression together with low M1/M2 ratio pattern correlated with poor outcome (p 5 0.001, hazard ratio 5 4.37, Table 1 ), suggesting that this expression pattern of concordant low Rab37 and sST2 and low ratio of M1/M2 markers is an independent biomarker for predicting poor prognosis.
Discussion
We previously reported that Rab37 was a metastasis suppressor. 33, 34 Here, we provide compelling evidence from cellbased, animal and clinical studies that Rab37 functions as a modulator of macrophage polarization via regulating the exocytosis of sST2, resulting in the preferential shift of macrophages phenotype from M2-like to M1-like, and thereby inhibiting tumor growth. Silencing of Rab37 reduced sST2 secretion into the extracellular compartment and thus resulted in pro-tumoral M2 macrophages activation in tumor microenvironment (Figs. 5f and 5g) . Our findings demonstrate for the first time that Rab37 regulates sST2 secretion to influence macrophages polarization in tumor microenvironment and reveal the interplay between vesicular exocytic machinery of cancer cells and immune cells in the regulation of tumor progression.
Recent study using engineered mice model has shown that epithelial-derived IL-33 increases ST2
1 regulatory T cells population, Th2 cytokines production and M2 macrophages infiltration to promote gut tumorigenesis. 38 Soluble ST2 has been shown to act as a decoy receptor to disrupt the signaling transduced by IL-33 to its membrane-bound receptor, ST2. 11, 15, 35 Consistently, we found that knockdown of sST2 in tumor cells displayed an in vivo growth advantage compared to control group (Fig. 3) , suggesting that tumorderived sST2 modulated tumor microenvironment to suppress tumor progression. Indeed, disruption of IL-33 and ST2 axis in breast cancer model in ST2-deficient mice showed reduced tumor growth and metastases.
13 IL-33 has been shown to induce the activation of Th1, CD8
1 T and NK cells to exert its anti-tumor activities. 39 However, this cytokine also mediates polarization of M2 macrophages and stimulates the development of myeloid-derived suppressor cells to promote tumorigenesis. For example, a recent study showed that IL-33 could promote the recruitment of macrophages into tumor regions and stimulated them toward pro-tumoral M2 polarization, thereby supporting tumor progression. 40 In patients with lung cancer, an inverse association of the levels of IL-33 in plasma or in tissue specimen with advanced tumor stage has been reported. 41, 42 However, it has also been revealed that expression of IL-33 in human lung tumor tissues is positively correlated with tumor progression. 43, 44 In addition, Barrera and associates have reported that circulating level of IL-33 is not associated with pathological outcomes in lung cancer patients. 45 This clearly reflects the diversity and complexity of the role of IL-33 in tumor progression. The correlation of ST2 expression in human lung cancer specimens with clinical outcome remains not clear. In our study, lung cancer patients with low ST2 expression correlated with advanced tumor stage, and showed significantly poorer prognosis than those with high expression of ST2. Consistent with our findings, Yang et al. has reported that downregulation of ST2 is observed in lung tumor tissues. 42 These results suggest that ST2-mediated signaling plays crucial roles in lung cancer progression.
Reconstitution of sST2 in Rab37-manipulated cancer cells demonstrated that Rab37 expression in cancer cells reduced M2 macrophage polarization and consequently led to decrease in tumor motility in vitro via mediation of sST2 secretion (Figs. 3 and 4) . We also demonstrated that macrophages pretreated with CM from Rab37-silenced cancer cells promoted tumor growth and metastases (Fig. 2) . Notably, the secretion of sST2 by Rab37 in cancer cells was critical for macrophages polarization in tumor microenvironment since deficiency in Rab37 or sST2 impaired the Rab37-or sST2-mediated suppression of tumor growth (Figs. 3 and 4) . Our results indicated that Rab37 expression in cancer cells influences the shaping of tumor microenvironment by regulating macrophages polarization.
The physiological and pathological functions of secreted ST2 glycoprotein were previously identified; however, the 
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secretion mode of ST2 has never been determined. We provided compelling evidence from both in vitro and in vivo experiments to confirm that Rab37-mediated exocytosis of sST2 in a GTP nucleotide-dependent manner, suggesting that active Rab37 has a crucial role in regulating sST2 secretion. Indeed, images from confocal microscopy illustrated colocalization of WT-or GTP-bound active Q89L-Rab37 and sST2 in cytoplasm, but not GDP-bound inactive T43N-Rab37 (Supporting information Fig. S3) . Our study provides a novel mechanism of how sST2 is secreted to the extracellular compartment by Rab37-mediated exocytosis.
Accumulating evidences have shown that a low ratio of M1/M2 macrophages is associated with poor prognosis in several cancer types. [46] [47] [48] CD86 and CD206 are widely used surface markers for characterization of M1 and M2 macrophages, respectively. Though a rare population of CD86-expressing dendritic cells (DC) exists in tumor microenvironment, monocytes and antigen-presenting cells also express CD86. In addition, the key features of activated macrophages are plasticity and flexibility. 49 Therefore, it raises the possibility that the pair of markers may be detected during M1-M2 transition stage, and it would not reflect the exact populations of M1 and M2 macrophages in the tumor regions. Our clinical analysis revealed that patients with low Rab37 expression, low sST2 expression together with low M1/M2 in tumors correlated with advanced tumor progression and poor overall survival (Fig. 5d) . Multivariate analysis showed that low ratio of M1/M2 combined with low Rab37 and low sST2 expression in patient biopsies was an independent prognostic factor in lung cancer patients (Table 1) . Indeed, Akimoto et al. has reported that the level of sST2 in circulation is negatively associated with advanced tumor stages in colorectal cancer patients. 11 These results suggested that sST2 could serve as a biomarker for cancer diagnosis.
In conclusion, our study provides a new insight into the role of Rab37 in tumor progression by mediating the exocytosis of sST2 in a GTP nucleotide-dependent manner to suppress M2 macrophage polarization and thus delaying lung cancer progression. Low expression of Rab37 and sST2 together with low ratio of M1/M2 macrophages in tumor region serves as an independent prognostic factor in lung cancer. Since DNA demethylation in Rab37 gene promoter increases Rab37 protein expression 32 and Rab37 protein stability can be regulated by N-terminal Met excision, 50 therapeutic agents activating the Rab37/ST2 axis to enhance the ratio of M1/M2 macrophages for reshaping of tumor microenvironment may provide better therapeutic benefit in lung cancer patients. 4 Patients were grouped according to Rab37 and ST2 expression, respectively. H, high expression for Rab37 and ST2; 1, for CD86/CD206 > 1; L, low expression for Rab37 and ST2; -, for CD86/CD206 < 1.
